Advertisement

Nuclear Binding of the Estrogen Receptor: Heterogeneity of Sites and Uterotropic Response

  • James H. Clark
  • Barry Markaverich
  • Susan Upchurch
  • Håkan Eriksson
  • James W. Hardin
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 117)

Summary

Two kinds of estradiol binding sites are present in purified nuclei from the rat uterus following estradiol injection. One of these sites (type I) corresponds to the well-known estrogen receptor which undergoes translocation from the cytoplasm to the nucleus. The second site (type II) is not translocated from the cytoplasm to the nucleus, however, estradiol treatment does stimulate an increased number of these sites. Type II sites are observed in purified nuclei and chromatin isolated from the uterus but not from non-target tissues such as the spleen and diaphragm. Thus an elevation in the levels of type II sites appear to be a specific nuclear response of the rat uterus to estradiol. Saturation analysis over a wide range of [3H]-estradiol concentrations produces a binding curve for type II sites which is sigmoidal and hence no accurate estimation of the dissociation constant is possible. The binding of [3H]-estradiol to nuclear type II sites is inhibited by estradiol and diethylstilbestrol but not by progesterone, testosterone, or corticosterone.

Extraction of nuclei isolated from estrogen treated rat uteri with KC1 provides a complex picture. Direct labeling of nuclear estrogen receptors either by in vivo injection or in vitro incubation of intact uteri with [3H]-estradiol measures only a fraction of the specific estrogen binding sites associated with the nuclear pellet following 0.4 M KC1 extraction. These sites are more accurately determined by performing saturation analysis over a wide range of [3H]-estradiol concentrations by exchange which measures specific estrogen binding sites, not [3H]-steroid. Saturation analysis of estradiol binding to KC1 extracted nuclei when performed by exchange, with appropriate corrections for type II binding, reveals that approximately 1000–2000 receptors per nucleus are resistant to KC1 extraction 1 hr after administration. The same numbers of type I sites display long-term nuclear retention.

A single injection of estradiol results in long term (>6 h) retention of type I sites, rapid and sustained elevations (1–72h) in type II sites and true uterine growth (uterine wet weight at 24–43 h). Estriol injection caused a rapid increase in nuclear type I sites which was not accompanied by an increase in type II sites and no true uterine growth occurred. Administration of estriol or estradiol as a pellet implant, which causes continuous occupancy of type I sites, increases the quantity of nuclear type II sites and stimulates true uterine growth. Therefore, we conclude that elevated levels of nuclear type II sites correlate with the long term uterotropic response to estrogenic hormones.

Although we do not understand the function of this second class of binding sites it is possible that the type II sites represent a major component in the mechanism by which estrogens stimulate growth of the uterus.

Keywords

Estrogen Receptor Salt Extraction Nuclear Pellet Nuclear Retention Estrogen Binding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    O’Malley, B.W. and Means, A.R. (1974) Science 183, 610–621.PubMedCrossRefGoogle Scholar
  2. 2.
    Gorski, J. and Gannon, F. (1976) Ann. Rev. Physiol. 38, 425–450.CrossRefGoogle Scholar
  3. 3.
    Yamamoto, K.R. and Alberts, B.M. (1976) Ann. Rev. Biochem. 45, 721–746.PubMedCrossRefGoogle Scholar
  4. 4.
    Clark, J.H., Peck, E.J., Jr., Hardin, J.W., and Eriksson, H. (1978) in Receptors and Hormone Action (O’Malley, B.W. and Birnbaumber, L., eds.) Vol. II, pp 1–31, Academic Press, New York.Google Scholar
  5. 5.
    Anderson, J.N., Clark, J.H., and Peck, E.J., Jr. (1972) Biochem. Biophys. Res. Commun. 48, 1460–1468.PubMedCrossRefGoogle Scholar
  6. 6.
    Anderson, J.N., Peck, E.J., Jr., and Clark, J.H. (1973) Endocrinology 92, 1488–1495.PubMedCrossRefGoogle Scholar
  7. 7.
    Clark, J.H. and Peck, E.J., Jr. (1976) Nature, London 260, 635–637.Google Scholar
  8. 8.
    Juliano, J.V. and Stancel, G.M. (1976) Biochemistry 15, 916–920.PubMedCrossRefGoogle Scholar
  9. 9.
    Traish, A.M., Muller, R.E., and Wotiz, H.H. (1977) J. Biol. Chem. 252, 6323–6830.Google Scholar
  10. 10.
    Muller, R.E., Traish, A.M., and Wotiz, H.H. (1977) J. Biol. Chem. 252, 8206–8211.Google Scholar
  11. 11.
    Ruh, T.S. and Baudendistel, L.J. (1977) Endocrinology 100, 420–426.PubMedCrossRefGoogle Scholar
  12. 12.
    Barrack, E.R., Hawkins, E.F., Allen, S.L., Hicks, L.L., and Coffey, D.S. (1977) Biochem. Biophys. Res. Commun. 79, 329–836.CrossRefGoogle Scholar
  13. 13.
    Eriksson, H., Upchurch, S., Hardin, J.W., Peck, E.J., Jr., and Clark, J.H. (1978) Biochem. Biophys. Res. Commun. 31, 1–7.CrossRefGoogle Scholar
  14. 14.
    Clark, J.H., Hardin, J.W., Upchurch, S., and Eriksson, H. (1978) J. Biol. Chem. In Press.Google Scholar
  15. 15.
    Clark, J.H., Paszko, Z., and Peck, E.J., Jr. (1977). Endocrinology 100, 91.PubMedCrossRefGoogle Scholar
  16. 16.
    Martucci, C. and Fishman, J. (1977). Endocrinology 101, 1709.PubMedCrossRefGoogle Scholar
  17. 17.
    Schibler, U. and Weber, R. (1974) Anal. Biochem. 58, 225–230.PubMedCrossRefGoogle Scholar
  18. 18.
    Hardin, J.W., Clark, J.H., Glasser, S.R., and Peck, E.J., Jr. (1976) Biochemistry 15, 1370–1374.PubMedCrossRefGoogle Scholar
  19. 19.
    Blobel, G. and Potter, V.R. (1966) Science 154, 1662–1664.PubMedCrossRefGoogle Scholar
  20. 20.
    Spelsberg, T.C., Hnilica, L.S., and Ansevin, A.T. (1971) Biochem. Biophys. Acta 228, 550–562.PubMedCrossRefGoogle Scholar
  21. 21.
    Rosenthal, H.E. (1967) Anal. Biochem. 20, 525–533.PubMedCrossRefGoogle Scholar
  22. 22.
    Losick, R. and Chamberlin, M. eds. (1976) RNA Polymerase Cold Springs Harbor Laboratory.Google Scholar
  23. 23.
    Anderson, J.N., Peck, E.J., Jr., and Clark J.H. (1975). Endocrinology 96, 160.PubMedCrossRefGoogle Scholar
  24. 24.
    Markaverich, B.M., Clark, J.H., and Hardin, J.W.H. (1978) Biochemistry 17, 3146.PubMedCrossRefGoogle Scholar
  25. 25.
    Anderson, J.N., Peck, E.J., Jr., and Clark, J.H. (1974) Endocrinology 95, 174.PubMedCrossRefGoogle Scholar
  26. 26.
    Hamilton, T.H. (1968) Science 161, 649–660.PubMedCrossRefGoogle Scholar
  27. 27.
    Clark, J.H., Hardin, J.W., Padykula, H.A., and Cardasis, C.A. (1978) Proc. Natl. Acad. Sci. U.S.A. 75, 2781–2784.PubMedCrossRefGoogle Scholar
  28. 28.
    Kohler, P.O., Grimley, P.M., and O’Malley, B.W. (1969) J. Cell Biol. 40, 8–27PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1979

Authors and Affiliations

  • James H. Clark
    • 1
  • Barry Markaverich
    • 1
  • Susan Upchurch
    • 1
  • Håkan Eriksson
    • 1
  • James W. Hardin
    • 1
  1. 1.Department of Cell BiologyBaylor College of MedicineUSA

Personalised recommendations